Measuring Attention During Immersive Virtual Reality Distraction
Launched by HUNTER HOFFMAN · Sep 23, 2024
Trial Information
Current as of June 30, 2025
Completed
Keywords
ClinConnect Summary
Healthy college student volunteers will participate in a repeated measure within subject trial studying attention using a divided attention paradigm.
One group of participants (16 healthy volunteers) will perform a simple attention demanding task during No VR for 2 minutes and they will perform the attention demanding task again during High Tech VR for 2 minutes.
Another group of 20 healthy volunteers will perform a simple attention demanding task during a less immersive see through VR (a plausible control condition) for 2 minutes and they will also perform the attention demanding task ag...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Currently enrolled in a course at the University of Washington Psychology Dept., participating in the University of Washington (UW) Psychology subject pool
- • Able to read, write and comprehend English
- • Able to complete study measures
- • Willing to follow our UW approved instructions
- • 18 years of age or older
- Exclusion Criteria:
- • People who have already previously participated in this same study (e.g., last quarter) are not eligible to participate again.
- • Not enrolled in a course at the University of Washington Psychology Dept., not participating in the UW Psychology subject pool
- • Not be able to read, write and comprehend English
- • Younger than 18 years of age.
- • Not capable of completing measures
- • Not capable of indicating pain intensity,
- • Not capable of filling out study measures,
- • Extreme susceptibility to motion sickness,
- • Seizure history,
- • Unusual sensitivity or lack of sensitivity to pain,
- • Sensitive skin,
- • Sensitive feet
- • Migraines
- • Diabetes
About Hunter Hoffman
Hunter Hoffman is a leading clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on cutting-edge methodologies and a commitment to scientific integrity, Hunter Hoffman collaborates with esteemed research institutions and healthcare professionals to design and conduct rigorous clinical trials. The organization prioritizes patient safety and ethical standards while striving to bring transformative treatments to market. Through its comprehensive approach, Hunter Hoffman aims to contribute significantly to the evolving landscape of healthcare and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Patients applied
Trial Officials
Hunter G Hoffman, Ph.D.
Principal Investigator
University of Washington
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported